α-bromoethyl acetate | 82198-80-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: α-bromoethyl acetate
• 英文别名: propionyl hypobromite；methyl bromo acetate；bromo methylacetate；bromo propanoate
• CAS: 82198-80-9
• 化学式: C₃H₅BrO₂
• 分子量: 152.975
• InChiKey: UCKZQZDVQVFOHP-UHFFFAOYSA-N

物化性质

• 沸点：
  179.33°C (rough estimate)
• 密度：
  1.4534 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  α-bromoethyl acetate 在 溴 作用下， 以 一氟三氯甲烷 为溶剂， 反应 0.25h， 生成 propionoxy radical
  参考文献：
  名称：

  Pivaloxy decarboxylates less rapidly than propionoxy: steric retardation of the decarboxylation of aliphatic carboxylate radicals

  摘要：

  DOI：

  10.1021/ja00380a038
• 作为产物：
  描述：

  silver(1+) propionate 在 溴 作用下， 以 一氟三氯甲烷 为溶剂， 生成 α-bromoethyl acetate
  参考文献：
  名称：

  Pivaloxy decarboxylates less rapidly than propionoxy: steric retardation of the decarboxylation of aliphatic carboxylate radicals

  摘要：

  DOI：

  10.1021/ja00380a038

文献信息

• NOVEL COMPOUNDS
  申请人：RUDOLF Klaus

  公开号：US20130150355A1

  公开（公告）日：2013-06-13

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R 1 , R 2 , R 3 , R 3a have meanings given in the description.

  这项发明涉及到式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍的药剂，如精神分裂症或认知功能下降，如痴呆症或认知障碍。A、B、Ar、R1、R2、R3、R3a在描述中有给定的含义。
• Chemokine receptor antagonists and methods of use thereof
  申请人：Luly R. Jay

  公开号：US20050070549A1

  公开（公告）日：2005-03-31

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.

  揭示了新化合物和一种治疗与异常白细胞召集和/或激活相关疾病的方法。该方法包括向需要的受试者施用由以下公式（1）表示的化合物或其生理上可接受的盐的有效量。
• 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：——

  公开号：US20030207937A1

  公开（公告）日：2003-11-06

  Compounds of the formula 1 where the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  具有公式1的化合物，其中变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，并且适用于治疗可通过视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。
• Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A
  申请人：——

  公开号：US20040077721A1

  公开（公告）日：2004-04-22

  vitamin A, or a derivative of vitamin A having vitamin A like activity is co-administered with inhibitors of the CP450RAI1 and/or of CP450RAI2 enzymes for the purpose of treating diseases and conditions in mammals, including humans, which diseases or conditions are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid.

  维生素A，或具有维生素A活性的维生素A衍生物与CP450RAI1和/或CP450RAI2酶的抑制剂共同给药，用于治疗哺乳动物，包括人类的疾病和状况，这些疾病或状况可以通过施用视黄酸化合物或通过哺乳动物机体自然存在的视黄酸来预防、治疗、改善或延迟其发作。
• Modulators of the cholesterol biosynthetic pathway
  申请人：——

  公开号：US20030191110A1

  公开（公告）日：2003-10-09

  The present invention relates to methods for modulating the cholesterol biosynthetic pathway. The level of cholesterol in the body is linked to numerous pathological states. The methods of the present invention alter the transcription levels of genes involved in the cholesterol biosynthesis. The methods of the present invention can used for treating diseases mediated by the cholesterol biosynthetic pathway.

  本发明涉及调节胆固醇生物合成途径的方法。体内胆固醇水平与许多病理状态相关。本发明的方法改变了参与胆固醇生物合成的基因的转录水平。本发明的方法可用于治疗由胆固醇生物合成途径介导的疾病。